NBIX — Neurocrine Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $12.34bn
- $11.31bn
- $1.89bn
- 99
- 29
- 73
- 74
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 788 | 1,046 | 1,134 | 1,489 | 1,887 |
Cost of Revenue | |||||
Gross Profit | 781 | 1,036 | 1,119 | 1,466 | 1,847 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 716 | 901 | 1,031 | 1,310 | 1,636 |
Operating Profit | 72.3 | 145 | 103 | 179 | 251 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 46.5 | 107 | 101 | 214 | 332 |
Provision for Income Taxes | |||||
Net Income After Taxes | 37 | 407 | 89.6 | 155 | 250 |
Net Income Before Extraordinary Items | |||||
Net Income | 37 | 407 | 89.6 | 155 | 250 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 37 | 407 | 89.6 | 155 | 250 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.67 | 5.38 | 1.87 | 2.09 | 3.9 |